Euroopan unioni - englanti - EMA (European Medicines Agency)

merz pharmaceuticals gmbh - memantine hydrochloride - alzheimer disease - other anti-dementia drugs - treatment of patients with moderate to severe alzheimer's disease.

Kanada - englanti - Health Canada

merz pharmaceuticals gmbh - incobotulinumtoxina - powder for solution - 100unit - incobotulinumtoxina 100unit - other miscellaneous therapeutic agents

Kanada - englanti - Health Canada

merz pharmaceuticals gmbh - incobotulinumtoxina - powder for solution - 50unit - incobotulinumtoxina 50unit - other miscellaneous therapeutic agents

Kanada - englanti - Health Canada

merz pharmaceuticals gmbh - incobotulinumtoxina - powder for solution - 100unit - incobotulinumtoxina 100unit - other miscellaneous therapeutic agents

Yhdysvallat - englanti - NLM (National Library of Medicine)

merz pharmaceuticals, llc - naftifine hydrochloride (unii: 25ur9n9041) (naftifine - unii:4fb1ton47a) - naftifine hydrochloride 2 g in 100 g

Yhdysvallat - englanti - NLM (National Library of Medicine)

merz pharmaceuticals, llc - dimethicone (unii: 92ru3n3y1o) (dimethicone - unii:92ru3n3y1o) - dimethicone 20 mg in 1 g - skin protectant - temporarily protects and helps relieve chapped or cracked skin

Yhdysvallat - englanti - NLM (National Library of Medicine)

merz pharmaceuticals, llc - dimethicone 2% - skin protectant - temporarily protects and helps relieve chapped or cracked skin

Yhdysvallat - englanti - NLM (National Library of Medicine)

merz north america, inc - polidocanol (unii: 0awh8bfg9a) (polidocanol - unii:0awh8bfg9a) - polidocanol 0.01000 g in 1 ml - asclera® (polidocanol) is indicated to sclerose uncomplicated spider veins (varicose veins ≤1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower extremity. asclera has not been studied in varicose veins more than 3 mm in diameter. asclera is contraindicated for patients with known allergy to polidocanol and patients with acute thromboembolic diseases. risk summary the available data from case reports on use of polidocanol-containing products, including asclera, in pregnant women have not identified any drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes. although none of these risks have been identified, there is minimal benefit in treating uncomplicated spider veins and reticular veins in the lower extremity during pregnancy and lower extremity varicosities that develop during pregnancy as they may spontaneously regress postpartum. the animal reproduction studies were conducted in a manner to achieve systemic e

Yhdysvallat - englanti - NLM (National Library of Medicine)

merz pharmaceuticals, llc - glycopyrrolate (unii: v92so9wp2i) (glycopyrronium - unii:a14fb57v1d) - glycopyrrolate 1 mg in 5 ml - cuvposa is indicated to reduce chronic severe drooling in patients aged 3 to 16 years with neurologic conditions associated with problem drooling (e.g., cerebral palsy). cuvposa is contraindicated in: - patients with medical conditions that preclude anticholinergic therapy (e.g., glaucoma, paralytic ileus, unstable cardiovascular status in acute hemorrhage, severe ulcerative colitis, toxic megacolon complicating ulcerative colitis, myasthenia gravis). - patients taking solid oral dosage forms of potassium chloride. the passage of potassium chloride tablets through the gastrointestinal (gi) tract may be arrested or delayed with coadministration of cuvposa. risk summary there are no available data in pregnant women for cuvposa to inform decisions concerning any drug-associated risks. in pregnant rats, daily oral administration of glycopyrrolate during organogenesis at dose exposures 2.5 to 113 times the exposure at the maximum recommended human dose (mrhd) did not result in an increased incidence of gross ex

Yhdysvallat - englanti - NLM (National Library of Medicine)

merz pharmaceuticals, llc - itraconazole (unii: 304nug5gf4) (itraconazole - unii:304nug5gf4) - itraconazole 200 mg - onmel is indicated for the treatment of onychomycosis of the toenail due to trichophyton rubrum or t. mentagrophytes in non-immunocompromised patients. prior to initiating treatment, appropriate nail specimens for laboratory testing (koh preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis of onychomycosis. [ see contraindications (4), warnings and precautions (5), drug interactions (7), and clinical pharmacology (12) .] congestive heart failure: do not administer onmel for the treatment of onychomycosis in patients with evidence of ventricular dysfunction such as congestive heart failure (chf) or a history of chf. [see warnings and precautions (5), drug interactions (7), and clinical pharmacology (12).] drug interactions: concomitant administration of onmel and certain drugs that are metabolized by the cytochrome p450 3a4 isoenzyme system (cyp3a4) or where gastrointestinal absorption is regulated by p-gp may result in increased plasma concentrations of those drugs, l